Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D.

Abigail L D TadenevCourtney L HattonRobert W Burgess

Published in: Journal of the peripheral nervous system : JPNS (2024)

Our results differ from those of two previous studies that demonstrated the benefit of the HDAC6 inhibitor tubastatin A in mouse models of CMT2D. While we cannot fully explain the different outcomes, our results offer a counterexample to the benefit of inhibiting HDAC6 in CMT2D, suggesting additional research is necessary.

Keyphrases

mouse model
histone deacetylase
signaling pathway
metabolic syndrome
copy number
weight loss